Thus, we elucidated the molecular mechanism of LCN2 inhibiting the migration and invasion of CRC cells and clarified that targeting the TGFB1/CXCL5 axis may be a novel approach for LCN2-related CRC therapy. This evidence concerns the gene LCN2 and colorectal carcinoma.